AMENDMENTS TO THE CLAIMS

1. **(Original)** Use of active dendritic cells (DCs) releasing interleukin 12 (IL-12) which are loaded with an antigen against a specific tumor and, due to the treatment with lipopolysaccaride (LPS) and interferon-gamma (IFN-γ), release IL-12, for the preparation of a medicament for treating a patient having said specific tumor.

2. **(Original)** Use according to claim 1, characterised in that said treatments is performed after bone marrow transplantation.

3. **(Currently Amended)** Use according to claim 1 ~~or 2~~, characterised in that said specific tumor is an advanced malignancy.

4. **(Currently Amended)** Use according to ~~any one of~~ claims 1 ~~to 3~~, characterised in that in said DCs are DCs having been taken from the patient having said specific tumor or from the bone marrow donor.

5. **(Currently Amended)** Use according to ~~any one of~~ claims 1 ~~to 4~~, characterised in that the DCs have been loaded with an antigen from a tumor cell from said patient having said specific tumor.

6. **(Currently Amended)** Use according to ~~any one of~~ claims ~~1 to~~ 5, characterised in, that the DCs are additionally charged with a tracer antigen.

7. **(Original)** Use according to claim 6, characterised in that said tracer antigen is keyhole limpet hemocyanine (KLH).

8. **(Currently Amended)** Use according to ~~any one of~~ claims ~~1 to~~ 7, characterised in that the DCs are additionally charged with an adjuvant, especially with tetanus toxoid.

9. **(Currently Amended)** Use according to ~~any one of~~ claims 1 ~~to 8~~, characterised in that

the DCs have been generated in vitro from peripheral blood mononuclear cells (PBMCs).

10. **(Original)** Composition for triggering IL-12 release from DCs containing LPS, IFN-γ and a tumor antigen.

11. **(Original)** Composition according to claim 10, characterised in that it is calf-serum free.

12. **(Original)** Use of a combination of LPS, IFN-γ and a tumor antigen for triggering IL-12 release from DCs.

13. **(Original)** Use according to claim 12, characterised in that the DCs have been loaded with an antigen from a tumor cell from a patient having said tumor.

14. **(Original)** Kit for triggering IL-12 release from DCs comprising

- LPS,
- IFN-γ and
- a tumor antigen.

15. **(Original)** Use of a kit according to claim 14 for triggering IL-12 release from DCs.

16. **(Original)** Use according to claim 15, characterised in that the DCs have been loaded with an antigen from a tumor cell from a patient having said tumor.